In November of 2003, AIDS Survival Project hosted our final two Treatment Forums of the year. The first, held on November 12, covered the new fusion inhibitor, Enfuvirtide, also known as Fuzeon. The following week, we hosted a forum on smoking cessation. Gerry Hoyt will review this Lunch & Learn in this issue of Survival News. I will report on Fuzeon. I will also take this opportunity to remind our readers that as with all the programs presented by ASP, our Treatment Forums remain free to the public.
Roche sponsored this forum, which was coordinated through the Treatment Education Program. When planning this event with David Nathison, with whom we have coordinated treatment education forums in the past, he was excited to add this additional forum to our roster. He had said that having done similar patient panel discussions in other metropolitan areas, the response was very positive. He wanted to add this additional forum to make sure Atlanta was included in this very casual yet informative exchange of the advantages and disadvantages of this new drug. Fuzeon holds promise for the HIV+ person who has taken (and has had fail) other anti-HIV drugs in the past. Because Fuzeon targets HIV differently than currently available drugs, chances are that most people living with the virus -- regardless of the medications they have taken in the past -- will likely benefit from using Fuzeon.
Depending on whether you count new formulations of existing drugs, there are now between twenty and twenty-four anti-HIV drugs in the U.S., including Fuzeon (T-20). Fuzeon represents a new class of drug known as entry or fusion inhibitors. When it was FDA-approved in March 2003, it came with two major obstacles. T-20 had to be injected subcutaneously twice daily, and it has a retail price of $25,000 a year -- nearly three times that of any existing drug.
The panelists were Steve Hightower, who is currently taking T-20 and a longtime patient at Pride Medical in Atlanta, Georgia; Dr. Jean Robinson, pharmacist and patient educator; and a Roche representative, who introduced the drug with a brief overview and who was there to answer technical questions. The following were the most asked questions.
The Roche representative replied, "Fuzeon is the most difficult antiretroviral to make, requiring over 100 steps for each batch, thus requiring us to charge a higher price than other drugs on the market."
No. On the web page www.HIVandHepatitis.com, eleven out of the fifty-six states and territories cover Fuzeon, while eight others plan to in the near future (early 2004). Georgia is discussing adding it to their formulary, but no immediate plans are confirmed at this time to include Fuzeon. For patient support, visit www.fuzeon.com or call (886) 487- 8591. Should this situation change, Survival News will keep you informed.
Fuzeon binds itself to a protein on HIVs surface, called gp41. Once it does this, HIV cannot successfully bind with the surface of T-cells, preventing the virus from infecting healthy cells.
Our thanks to Steve for his willingness to speak plainly about his experience with Fuzeon and to Jean, who also volunteers with THRIVE! Weekend.
The Treatment Resource Center (TRC) at ASP features a complete binder on Fuzeon, which includes information on drug interactions, when and who should consider taking it and injection tips. For Fuzeons patient support, visit www.fuzeon.com or call toll-free 1-877-438-9366. I encourage you to give us a call at (404) 874-7926 or come visit us in the TRC for more information on Fuzeon, as well as the latest information on other treatments. Of course, if you cant visit, we will mail any information you need.
Watch for our upcoming Treatment Forums in Survival News. As I reflect on 2003, a thought comes to mind: The Good, the Bad and the Ugly.
As always, keep safe!